Skip to main content
Fig. 4 | World Journal of Surgical Oncology

Fig. 4

From: LncRNA MSTO2P promotes colorectal cancer progression through epigenetically silencing CDKN1A mediated by EZH2

Fig. 4

MSTO2P interacts with EZH2 to inhibit CDKN1A transcription. A The distribution of MSTO2P in HT-29 cells was evidenced by RT-qPCR assay. B RT-qPCR assay showed that si-MSTO2P upregulated CDKN2B, CDKN1A, Bax, EMP1, and PTEN expression level and decreased Bcl-2 level in HT-29 cells. C Western blot assay showed that si-MSTO2P upregulated CDKN1A protein level. D Bioinformatics were used to predict the interaction probabilities of lncRNA MSTO2P and EZH2 via RNA-protein interaction prediction (http://pridb.gdcb.iastate.edu/rpiseq/). Predictions with probabilities >0.5 were considered positive. E RIP assay confirmed that MSTO2P was directly bound to EZH2 in HT-29 cells. F RT-qPCR assay showed si-EZH2 significantly enhanced CDKN1A expression level. G Western blot assay showed si-EZH2 significantly enhanced CDKN1A expression level. H CHIP assay showed that si-MSTO2P suppressed binding of EZH2 and H3K27me3. *p<0.05, **p<0.01, and ***p<0.001

Back to article page